Clinical Trial Update: Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating buparlisib (BKM120) in combination with tamoxifen for HR-positive, HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BKM120 (Buparlisib)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: University Hospital, Essen | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED